Sign Out
FEIBA is used for the treatment and prophylaxis of hemorrhages in hemophilia A and B patients with inhibitors.
Furthermore, FEIBA can be used for the treatment and prophylaxis of hemorrhages in non-hemophilic patients who have developed inhibitors to Factors VIII, IX and XI.
Individual reports exist about the use of FEIBA in the treatment of patients with acquired inhibitors to Factors X and XIII.
FEIBA was also used in the combination with Factor VIII concentrate for a long-term therapy to achieve a complete and permanent elimination of the Factor VIII inhibitor so as to allow for regular treatment with Factor VIII concentrate as in patients without inhibitor.
